Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.37 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2239281 | 1.00 | MEN1 (0.41) | MEN1KMT2AOPRL1KCNH2SLC6A4 | |
| Hydrochloric Acid SCHEMBL15017219 | 0.98 | OPRL1 (0.40) | MEN1KMT2AOPRL1KCNH2SLC6A4 | |
| Hydrochloric Acid SCHEMBL15017218 | 0.98 | OPRL1 (0.40) | MEN1KMT2AOPRL1KCNH2SLC6A4 | |
| SCHEMBL24654623 | 0.94 | OPRL1 (0.44) | MEN1KMT2AOPRL1KCNH2SLC6A4 | |
| SCHEMBL28519635 | 0.87 | MEN1 (0.44) | MEN1KMT2AOPRL1KCNH2SLC6A4 | |
| SCHEMBL25316221 | 0.87 | MEN1 (0.44) | MEN1KMT2AOPRL1KCNH2SLC6A4 | |
| SCHEMBL932672 | 0.83 | KDM1A (0.44) | MEN1KMT2AKCNH2CHRM5CHRM3 | |
| SCHEMBL22917359 | 0.83 | KDM1A (0.44) | MEN1KMT2AKCNH2CHRM5CHRM3 | |
| SCHEMBL29404068 | 0.83 | KDM1A (0.44) | MEN1KMT2AKCNH2CHRM5CHRM3 | |
| SCHEMBL933161 | 0.83 | KDM1A (0.44) | MEN1KMT2AKCNH2CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072451-A1 | RAS-PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOLOGICAL DISEASES | VIVIDION THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20240132500-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC (US) | 2024-04-25 | — | — | US | disclosed |
| US-20230234955-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC (US) | 2023-07-27 | — | — | US | disclosed |
| US-11267818-B2 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | ARRAY BIOPHARMA INC. (US) | 2022-03-08 | — | — | US | disclosed |
| EP-3372605-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2021-11-03 | — | — | EP | disclosed |
| US-20210002287-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC. | 2021-01-07 | — | — | US | disclosed |
| US-10774085-B2 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds | ARRAY BIOPHARMA INC. (US) | 2020-09-15 | — | — | US | disclosed |
| CN-109053525-B | Preparation method of (R) -2- (2-substituted-5-fluorobenzene) pyrrolidine | 成都福柯斯医药技术有限公司 | 2020-05-05 | — | — | CN | disclosed |
| US-20190211017-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC. | 2019-07-11 | — | — | US | disclosed |
| EP-3372605-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2018-09-12 | — | — | EP | disclosed |
| US-20150133429-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-a] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA, INC. | 2015-05-14 | — | — | US | disclosed |
| US-20150005499-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA, INC. | 2015-01-01 | — | — | US | disclosed |
| US-8865698-B2 | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds | ARRAY BIOPHARMA INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140194403-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC. (US) | 2014-07-10 | — | — | US | disclosed |
| EP-2725028-A1 | Substituted pyrazolo[1,5-]pyrimidine compounds as intermediates in the synthesis of TRK kinase inhibitors | Array Biopharma, Inc. (US) | 2014-04-30 | — | — | EP | disclosed |
| EP-2350071-B1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2014-01-08 | — | — | EP | disclosed |
| US-8513263-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110195948-A1 | Substituted Pyrazolo[1,5-a]Pyrimidine Compounds as TRK Kinase Inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-08-11 | — | — | US | disclosed |
| EP-2350071-A1 | SUBSTITUTED PYRAZOLOÝ1,5-a¨PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010048314-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11267818-B2 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | TYMP, TYMS, P2RX7 | MEN1 4187/4885KMT2A 3389/4885OPRL1 701/4885 |
| US-20240132500-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, P2RX7 | MEN1 4187/4885KMT2A 3389/4885OPRL1 701/4885 |
| US-20110195948-A1 | Substituted Pyrazolo[1,5-a]Pyrimidine Compounds as TRK Kinase Inhibitors | PDXK, DTYMK, TNNI3K | MEN1 2927/4885KMT2A 2437/4885OPRL1 2418/4885 |
| US-20190211017-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, P2RX7 | MEN1 4187/4885KMT2A 3389/4885OPRL1 701/4885 |
| US-20230234955-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, TK1 | MEN1 4351/4885KMT2A 3339/4885OPRL1 883/4885 |
| US-10774085-B2 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds | TYMP, TYMS, P2RX7 | MEN1 4187/4885KMT2A 3389/4885OPRL1 701/4885 |
| US-20150133429-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-a] PYRIMIDINE COMPOUNDS | TYMP, TYMS, P2RX7 | MEN1 4187/4885KMT2A 3389/4885OPRL1 701/4885 |
| US-20210002287-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, P2RX7 | MEN1 4187/4885KMT2A 3389/4885OPRL1 701/4885 |
| US-20140194403-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS | P2RX7, P2RX1, P2RX3 | MEN1 3917/4885KMT2A 3101/4885OPRL1 178/4885 |
| US-20150005499-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS | TYMP, TYMS, P2RX7 | MEN1 4187/4885KMT2A 3389/4885OPRL1 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.